This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Goflikicept
- DrugBank Accession Number
- DB16396
- Background
Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2) Infection (COVID-19)).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Fusion proteins - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Goflikicept
- Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
- RPH-104
- External IDs
- RPH 104
- RPH-104
- RPH104
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Goflikicept is a fusion protein that neutralizes interleukin-1B (IL-1B), affecting its signalling pathways. As IL-1B is involved in 'cytokine storm' efects, goflikicept's effects on the molecule inhibits widespread inflammation.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 11DRN01OK2
- CAS number
- 2416984-26-2
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Idiopathic Recurrent Pericarditis 1 3 Not Yet Recruiting Treatment Adult Onset Still's Disease / AOSD 1 2 Completed Treatment Acute Myocardial Infarction With ST Segment Elevation 1 2 Not Yet Recruiting Treatment Schnitzler's Syndrome / Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder) 1 2 Recruiting Treatment Familial Mediterranean Fever (FMF ) / FMF 2 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) / Gout attack 1 2, 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 2, 3 Completed Treatment Pericarditis 1 2, 3 Not Yet Recruiting Treatment Recurrent Pericarditis 1 1 Completed Other Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 23, 2020 16:14 / Updated at July 18, 2023 22:58